Galena Biopharma (GALE)
Add to Watchlists Create an AlertGalena Biopharma Enterprise Value:
177.21M for May 24, 2013Galena Biopharma Historical Enterprise Value Data
Pro Data ExportThere is no data for the selected date range.
| Data for this Date Range | |
|---|---|
| May 24, 2013 | 177.21M |
| May 23, 2013 | 180.53M |
| May 22, 2013 | 178.87M |
| May 21, 2013 | 172.23M |
| May 20, 2013 | 169.32M |
| May 17, 2013 | 166.41M |
| May 16, 2013 | 172.23M |
| May 15, 2013 | 176.38M |
| May 14, 2013 | 173.06M |
| May 13, 2013 | 178.04M |
| May 10, 2013 | 188.01M |
| May 9, 2013 | 191.34M |
| May 8, 2013 | 190.50M |
| May 7, 2013 | 187.18M |
| May 6, 2013 | 194.66M |
| May 3, 2013 | 170.56M |
| May 2, 2013 | 166.41M |
| May 1, 2013 | 197.98M |
| April 30, 2013 | 202.97M |
| April 29, 2013 | 193.00M |
| April 26, 2013 | 175.55M |
| April 25, 2013 | 169.73M |
| April 24, 2013 | 168.90M |
| April 23, 2013 | 159.76M |
| April 22, 2013 | 157.27M |
| April 19, 2013 | 163.92M |
| April 18, 2013 | 153.12M |
| April 17, 2013 | 157.27M |
| April 16, 2013 | 158.93M |
| April 15, 2013 | 145.64M |
| April 12, 2013 | 154.78M |
| April 11, 2013 | 168.07M |
| April 10, 2013 | 155.61M |
| April 9, 2013 | 144.81M |
| April 8, 2013 | 137.33M |
| April 5, 2013 | 135.67M |
| April 4, 2013 | 134.01M |
| April 3, 2013 | 131.51M |
| April 2, 2013 | 134.84M |
| April 1, 2013 | 136.50M |
| March 28, 2013 | 138.96M |
| March 27, 2013 | 138.96M |
| March 26, 2013 | 137.30M |
| March 25, 2013 | 137.30M |
| March 22, 2013 | 124.84M |
| March 21, 2013 | 123.59M |
| March 20, 2013 | 126.50M |
| March 19, 2013 | 126.91M |
| March 18, 2013 | 132.31M |
| March 15, 2013 | 124.00M |
About Enterprise Value
Click "Learn More" below to see how YCharts calculates Enterprise Value.
Enterprise Value (EV) is a valuation metric alternative to traditional market capitalization that reflects the market value of an entire business. Like market cap, EV is a measure of what the market believes a company is worth. Enterprise value captures the cost of an entire business, including debt and equity. It is a sum of claims of all preferred shareholders, debt holders, security holders, common equity holders, and minority shareholders - unlike market cap, which only captures the total value of common equity securities.
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Learn More
GALE Enterprise Value Benchmarks
| Companies | |
|---|---|
| AVEO Pharmaceuticals | -24.91M |
| Achillion Pharmaceuticals | 587.52M |
| InterMune | 601.40M |
GALE Enterprise Value Rankings
| Overall |
55th percentile 3360 of 7600 |
| Sector |
49th percentile 327 of 653 in Healthcare |
| Industry |
60th percentile 94 of 238 in Biotechnology |
GALE Enterprise Value Range, Past 5 Years
| Minimum | 0.7589M | Dec 19 2011 |
| Maximum | 202.97M | Apr 30 2013 |
| Average | 63.42M |
